<DOC>
	<DOCNO>NCT00141778</DOCNO>
	<brief_summary>Atrial fibrillation ( AF ) prevalent , sustain type irregular heartbeat affect 2 million Americans . Post-operative AF , lead significant morbidity prolong hospital stay , complicate 20 % 40 % cardiopulmonary bypass ( CPB ) surgical procedure . While recent study indicate interruption renin-angiotensin-aldosterone system either angiotensin-converting enzyme ( ACE ) inhibition AT1 receptor antagonism decrease incidence AF follow heart attack cardioversion ( electric shock heart ) , effect incidence post-operative AF throughly study . Studies animal human suggest inflammation-induced atrial remodeling play important role cause AF . Recent study also provide evidence activation renin-angiotensin-aldosterone system induce inflammation , myocyte injury , proarrhythmic electrical remodeling , fibrosis aldosterone .</brief_summary>
	<brief_title>Renin-angiotensin-aldosterone System ( RAAS ) , Inflammation , Post-Operative Atrial Fibrillation ( AF )</brief_title>
	<detailed_description>AF prevalent , sustain type irregular heartbeat affect 2 million Americans . Post-operative atrial fibrillation ( AF ) , lead significant morbidity prolong hospital stay , complicate 20 % 40 % CPB surgical procedure . While recent study indicate interruption renin-angiotensin-aldosterone system either angiotensin-converting enzyme ( ACE ) inhibition angiotensin II subtype 1 ( AT1 ) receptor antagonism decrease incidence AF follow heart attack cardioversion ( electric shock heart ) , effect incidence post-operative AF throughly study . Studies animal human suggest inflammation-induced atrial remodeling play important role cause AF . Recent study also provide evidence activation renin-angiotensin-aldosterone system induce inflammation , myocyte injury , proarrhythmic electrical remodeling , fibrosis aldosterone . This study evaluate effectiveness ACE inhibition aldosterone receptor antagonism decrease inflammation AF follow cardiopulmonary bypass ( CPB ) surgery .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Mineralocorticoids</mesh_term>
	<criteria>1 . Undergoing elective valvular heart surgery , coronary artery bypass graft 2 . If female , must postmenopausal least 1 year , statuspost surgical sterilization , childbearing potential , utilizing adequate birth control willing undergo urine betahcg test prior drug treatment throughout study Exclusion Criteria 1 . History AF remote paroxysmal AF 2 . Ejection fraction le 30 % 3 . Evidence coagulopathy ( INR great 1.7 without warfarin therapy ) 4 . Emergency surgery 5 . History ACE inhibitorinduced angioedema 6 . Low blood pressure ( systolic blood pressure le 100 mmHg evidence hypoperfusion ) 7 . Hyperkalemia ( potassium level great 5.0 milliequivalent ( mEq ) /L study entry ) 8 . Impaired kidney function ( serum creatinine level great 1.6 mg/dl ) 9 . Any underlying acute disease require regular medication could possibly cause complication make implementation study interpretation study result difficult 10 . Inability discontinue current ACE inhibitor , AT1 receptor antagonist , aldosterone receptor antagonist therapy 11 . History alcohol drug abuse 12 . Treatment investigational drug month prior study entry 13 . Mental condition make impossible understand nature , scope possible consequence study 14 . Inability comply study procedure ( e.g. , uncooperative attitude , inability return followup visit , unlikelihood complete study ) 15 . Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>cardiac surgery</keyword>
</DOC>